209 followers
#Correction to: Safety and efficacy of #nivolumab in combination with #sunitinib or #pazopanib in advanced or metastatic renal cell carcinoma: the #CheckMate 016 study. #RenalCellCarcinoma #RCC @ERPlimackMD @FCUroOnc @FoxChaseCancer https://t.co/ktJLi2yesJ